Division of AIDS Office of the Director Workforce Operations,

Slides:

Advertisements

Similar presentations

Your Tax Dollars at Work: Community Participation in DAIDS Funded HIV Clinical Trials Claire Rappoport, Dwight Peavy, Hamilton Richardson and Rona Siskind.

Advertisements

UCSF and Global Health Institutional Infrastructure for Global Health Projects Role of Surgery and Global Health Future Opportunities and Research.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

Long-term Projections of the Cost of Treatment Under Various Scenarios – Opportunities for Efficiency and Effectiveness? Arin Dutta, Cathy Barker, and.

The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.

Key Policy Issues: 2013 Pan-African Parliament / UNAIDS Dialogue Pride Chigwedere, MD, PhD Senior Advisor, UNAIDS Liaison Office to the AU.

Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,

TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.

Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.

EoI assesment and presentation NCP 24 October 2002 Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related.

Global Health Program Guiding Principles April 2002.

Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.

AIDS Vaccine R&D (post-AIDSVAX®). R&D challenges Products in development Funding AIDS vaccine R&D Access and advocacy.

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPACT) Group PROMISE (BREAST FEEDING) 1077 AAHU STC 2013 Group 2 Cedric Sturdevant,

Community Representation Structure. Site Coordinating Centers (SCC) Community Advisory Boards (CABs) Leadership Level Cross-Network Level Network Level.

06/17/09 Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD HIV Research Scientific Priorities Lynne Mofenson MD, Branch.

Jacques Normand, Ph.D. Director, AIDS Research Program National Institute on Drug Abuse NIDA’s New HIV/AIDS Research Program.

Global Campaign for Microbicides Rebekah Webb, European Coordinator

The South African perspective

1 Promotoras, Peer Participant Providers and Community Outreach as Preconception in the Continuum of Perinatal HIV Transmission Armida Ayala, M.H.A., Ph.D.

What Makes a Successful Trial? MorenikeUkpong Nigeria HIV Vaccine and Microbicide Advocacy Group.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

OFFICE OF AIDS RESEARCH DHHS/NIH/OAR NIH AIDS Research Priorities Jack Whitescarver, Ph.D. NIH Associate Director for AIDS Research and Director, OAR May.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Welcome to “STD 101 in a Box” Developed by Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.

HANC and Community Partners Overview November 20, 2007 Michael Petillo, Project Coordinator.

Agenda Introduction- Jessica Rodrigues, IATT Paediatric Treatment Optimization- George Silberry, Senior Technical Advisor for Pediatric HIV, OGAC Optimal.

Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.

Update on the Development of a Group A Streptococcal Vaccine Fran A. Rubin, Ph.D. Program Officer for Group A Streptococci Respiratory Diseases Branch.

Evidence for optimizing highly active antiretroviral treatment (HAART) in Kenya Dr. Washingtone Ochieng CNHR RCDG Fellow returning from Harvard University,

2008 International AIDS Conference UNGASS reporting Matthew Warner-Smith Monitoring and Evaluation Division UNAIDS 2008 International AIDS Conference Satellite.

Adolescent Family Life Program Office of Population Affairs Office of Adolescent Pregnancy Programs November 2009.

Janet Heitgerd, PhD Program Evaluation Branch, Associate Chief for Science American Evaluation Association Annual Meeting November 2010 Improving the Design,

HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities

Maternal Toxicity Management

JULY 2014 CHIEF EXECUTIVE DIRECTOR OF PATIENT ACCESS SITE TEAM

Monitoring and evaluation of disability-inclusive development

Preclinical Pathway to Host-Directed Therapy for TB/HIV Co-Infection

27 years of responding to AIDS

Faculty of Population Health Dean: Graham Hart

Maternal Toxicity Management

Maternal Toxicity Management

27 years of responding to AIDS

Global epidemiology of injecting drug use

Community Advocacy & Education to End Stigmatizing HIV/TB Language

Access Equity in Prisons in Africa A CALL FOR ACTION

Stop TB Partnership Secretariat (TBP)

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

World Health Organization

The Commission Strategy on TB vaccine research

What Will It Take To End Pediatric AIDS

27 years of responding to AIDS

Antibiotic Resistance: Strategic Solutions

World Health Organization

PRIVATE AND THE PUBLIC SECTORS & HEALTHCARE SERVICES BY ROBERT BASAZA

Jeffrey D. Sachs, PhD Director, Center for International Development

Socio-structural protection from self-stigma among South African adolescents living with HIV: The potential of clinic-community collaborations for stigma.

MTN 037 Recruitment and Retention

Clinical and Translational Science Awards Program

Intl Director of Campaigns Director of Policy & External Affairs

TB VACCINES WORKING GROUP

Lessons Learned from Sustained Global Health Investments:

Background to ProTEST and its Role in TB/HIV Agenda-setting

Every Mother, Every Child: Closing the Gaps in HIV Management

The STOP TB Strategy – 2009 VISION: A TB-free world

Children (<15 years) estimated to be living with HIV as of end 2005

Evaluating International Drug and Therapeutics Committees Courses in the Developing World

Cumulative number of HIV infections

TB-HIV/AIDS Co-Infection Coordination among Programs

Presentation transcript:

Division of AIDS Office of the Director Workforce Operations, Communications, & Reporting Branch Science Planning & Operations Branch Office for Policy in Clinical Research Operations Basic Sciences Program Prevention Sciences Program Therapeutics Research Program Vaccine Research Program Office of Clinical Site Oversight Clinical Research Resources Branch Epidemiology Branch Clinical Microbicide Research Branch HIV Research Branch Preclinical R&D Branch Pharmaceutical Affairs Branch Regulatory Affairs Branch Pathogenesis & Basic Research Branch Clinical Prevention Research Branch Complications & Co-infections Research Branch Vaccine Clinical Research Branch Monitoring and Operations Branch Protection of Participants, Evaluation and Policy Branch Targeted Interventions Branch Preclinical Microbicide and Prevention Research Branch Drug Development and Clinical Sciences Branch Asia and the Americas Branch Vaccine Translational Research Branch TB Clinical Research Branch Africa and the Domestic Partners Branch Maternal, Adolescent & Pediatric Research Branch